Pitt Street Research | Stock research
Atomo.png

Atomo Diagnostics

Atomo Diagnostics (ASX:AT1) develops unique 'user-friendly' Rapid Diagnostic Tests (RDTs). Atomo’s technology was developed as a test device platform with the initial clinical application focused on HIV/AIDs where the first products were launched in 2018. The company is at a major juncture where it is building a more comprehensive pipeline.

Atomo Diagnostics (ASX:AT1)

 

Atomo Diagnostics (ASX:AT1) develops unique 'user-friendly' Rapid Diagnostic Tests (RDTs). Atomo’s technology was developed as a test device platform with the initial clinical application focused on HIV/AIDs where the first products were launched in 2018. The company is at a major juncture where it is building a more comprehensive pipeline.

14 May 2025: We spoke with John Kelly, CEO of Atomo Diagnostics (ASX: AT1) about the company's progress with its new syphilis diagnostic and the building out of its diagnostics pipeline. We also talked about AT1's continued success with its core HIV diagnostic franchise. Atomo's diagnostics are highly differentiated from the current standard of care, increasing the coming commercial payoff.